172 related articles for article (PubMed ID: 21127197)
1. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions.
Towle MJ; Salvato KA; Wels BF; Aalfs KK; Zheng W; Seletsky BM; Zhu X; Lewis BM; Kishi Y; Yu MJ; Littlefield BA
Cancer Res; 2011 Jan; 71(2):496-505. PubMed ID: 21127197
[TBL] [Abstract][Full Text] [Related]
2. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389.
Kuznetsov G; Towle MJ; Cheng H; Kawamura T; TenDyke K; Liu D; Kishi Y; Yu MJ; Littlefield BA
Cancer Res; 2004 Aug; 64(16):5760-6. PubMed ID: 15313917
[TBL] [Abstract][Full Text] [Related]
3. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase.
Okouneva T; Azarenko O; Wilson L; Littlefield BA; Jordan MA
Mol Cancer Ther; 2008 Jul; 7(7):2003-11. PubMed ID: 18645010
[TBL] [Abstract][Full Text] [Related]
5. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth.
Jordan MA; Kamath K; Manna T; Okouneva T; Miller HP; Davis C; Littlefield BA; Wilson L
Mol Cancer Ther; 2005 Jul; 4(7):1086-95. PubMed ID: 16020666
[TBL] [Abstract][Full Text] [Related]
6. Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation.
Alday PH; Correia JJ
Biochemistry; 2009 Aug; 48(33):7927-38. PubMed ID: 19586046
[TBL] [Abstract][Full Text] [Related]
7. Eribulin shows high concentration and long retention in xenograft tumor tissues.
Sugawara M; Condon K; Liang E; DesJardins C; Schuck E; Kusano K; Lai WG
Cancer Chemother Pharmacol; 2017 Aug; 80(2):377-384. PubMed ID: 28664226
[TBL] [Abstract][Full Text] [Related]
8. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
Kawano S; Asano M; Adachi Y; Matsui J
Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
Devriese LA; Witteveen PE; Wanders J; Law K; Edwards G; Reyderman L; Copalu W; Peng F; Marchetti S; Beijnen JH; Huitema AD; Voest EE; Schellens JH
Br J Clin Pharmacol; 2013 Feb; 75(2):507-15. PubMed ID: 22803519
[TBL] [Abstract][Full Text] [Related]
10. The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner.
Hüsemann LC; Reese A; Radine C; Piekorz RP; Budach W; Sohn D; Jänicke RU
Cell Cycle; 2020 Feb; 19(4):464-478. PubMed ID: 31959066
[TBL] [Abstract][Full Text] [Related]
11. MJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells.
Yang JS; Hour MJ; Huang WW; Lin KL; Kuo SC; Chung JG
J Pharmacol Exp Ther; 2010 Aug; 334(2):477-88. PubMed ID: 20463006
[TBL] [Abstract][Full Text] [Related]
12. [Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
Koyama N; Tokunaga T; Ogasawara W; Murakami M; Yamashita Y
Nihon Yakurigaku Zasshi; 2011 Nov; 138(5):209-17. PubMed ID: 22075465
[No Abstract] [Full Text] [Related]
13. Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Majid O; Gupta A; Reyderman L; Olivo M; Hussein Z
J Clin Pharmacol; 2014 Oct; 54(10):1134-43. PubMed ID: 24771603
[TBL] [Abstract][Full Text] [Related]
14. Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation.
Mohan R; Banerjee M; Ray A; Manna T; Wilson L; Owa T; Bhattacharyya B; Panda D
Biochemistry; 2006 May; 45(17):5440-9. PubMed ID: 16634625
[TBL] [Abstract][Full Text] [Related]
15. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications.
Cortes J; Schöffski P; Littlefield BA
Cancer Treat Rev; 2018 Nov; 70():190-198. PubMed ID: 30243063
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B.
Towle MJ; Salvato KA; Budrow J; Wels BF; Kuznetsov G; Aalfs KK; Welsh S; Zheng W; Seletsky BM; Palme MH; Habgood GJ; Singer LA; Dipietro LV; Wang Y; Chen JJ; Quincy DA; Davis A; Yoshimatsu K; Kishi Y; Yu MJ; Littlefield BA
Cancer Res; 2001 Feb; 61(3):1013-21. PubMed ID: 11221827
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
18. Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
Narayan S; Carlson EM; Cheng H; Condon K; Du H; Eckley S; Hu Y; Jiang Y; Kumar V; Lewis BM; Saxton P; Schuck E; Seletsky BM; Tendyke K; Zhang H; Zheng W; Littlefield BA; Towle MJ; Yu MJ
Bioorg Med Chem Lett; 2011 Mar; 21(6):1634-8. PubMed ID: 21324692
[TBL] [Abstract][Full Text] [Related]
19. Eribulin in Cancer Treatment.
Swami U; Shah U; Goel S
Mar Drugs; 2015 Aug; 13(8):5016-58. PubMed ID: 26262627
[TBL] [Abstract][Full Text] [Related]
20. Termination of Protofilament Elongation by Eribulin Induces Lattice Defects that Promote Microtubule Catastrophes.
Doodhi H; Prota AE; Rodríguez-García R; Xiao H; Custar DW; Bargsten K; Katrukha EA; Hilbert M; Hua S; Jiang K; Grigoriev I; Yang CH; Cox D; Horwitz SB; Kapitein LC; Akhmanova A; Steinmetz MO
Curr Biol; 2016 Jul; 26(13):1713-1721. PubMed ID: 27321995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
